ChiCTR-CCC-14004202 版本V1.0 版本创建时间2016/08/07 18:02:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-CCC-14004202 

最近更新日期:

Date of Last Refreshed on:

2015-05-01 16:09:37 

注册时间:

Date of Registration:

2014-01-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

Meige综合征易感性及肉毒菌素A疗效研究

Public title:

Meige syndrome susceptibility and BTA efficacy research

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Meige综合征易感性及肉毒菌素A疗效研究

Scientific title:

Meige syndrome susceptibility and BTA efficacy research

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

屈健 

研究负责人:

刘昭前 

Applicant:

Jian Qu 

Study leader:

Zhaoqian Liu 

申请注册联系人电话:

Applicant telephone:

+86 15973190614

研究负责人电话:

Study leader's
telephone:

+86 13787797720

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mokaxixi@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

liuzhaoqian63@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

长沙湘雅路110号中南大学临床药理研究所

研究负责人通讯地址:

长沙湘雅路110号中南大学临床药理研究所

Applicant address:

110 Xiangya road, Institution of Clinical Pharmacology

Study leader's address:

110 Xiangya road, Institution of Clinical Pharmacology

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学临床药理研究所

Applicant's institution:

Institution of Clinical Pharmacology, CSU

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CTXY140001

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中南大学临床药理研究所伦理委员会

Name of the ethic committee:

Ethics Committee Institution of Clinical Pharmacology, Cental South University

伦理委员会批准日期:

Date of approved by ethic committee:

2014-01-14 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学临床药理研究所

Primary sponsor:

Institution of Clinical Pharmacology, Cental South University

研究实施负责(组长)单位地址:

长沙湘雅路110号中南大学临床研究研究所

Primary sponsor's address:

110 Xiangya road, Institution of Clinical Pharmacology, Cental South University

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

湘雅医院

具体地址:

长沙湘雅路110号

Institution
hospital:

Xiangya Hospital

Address:

110 Xiangya Road, Changsha, Hunan, China

经费或物资来源:

国家863计划

Source(s) of funding:

863 program

研究疾病:

Meige综合征  

Target disease:

Meige syndrome

研究疾病代码:

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

对Meige综合征易感性及肉毒菌素A疗效进行相关研究,找出易感基因及影响肉毒菌素A疗效因素。  

Objectives of Study:

to known well about the eiology of Meige syndrome and the efficacy of BTA

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经神经内科医生诊断的Meige综合征病人。
2.健康人

Inclusion criteria

1. To be diagnosed by neurologists Meige syndrome patients;
2. healthy controls.

排除标准:

非Meige综合征病人。

Exclusion criteria:

non-Meige snydrome patients

研究实施时间:

Study execute time:

From 2014-02-01 00:00:00 To 2014-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2014-02-01 00:00:00 To 2014-06-30 00:00:00

干预措施:

Interventions:

组别:

Meige综合症

样本量:

100

Group:

Meige snydrome patients

Sample size:

干预措施:

BTA 50U注射

干预措施代码:

Intervention:

BTA 50U injection.

Intervention code:

组别:

对照

样本量:

100

Group:

Healthy control

Sample size:

干预措施:

NA

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

湘雅医院 

单位级别:

3甲 

Institution
hospital:

Xiangya Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

药物保持时间

指标类型:

主要指标

Outcome:

maintain time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血样

组织:

Sample Name:

blood

Tissue:

no

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2014-01-25 00:00:00